# Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

Study · id `cardio:ct-nct06215586` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06215586](<https://clinicaltrials.gov/study/NCT06215586>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06215586

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 303 participants.

## Technical summary

Registry record NCT06215586. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-13 (actual); primary completion 2025-09-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 303 participants (enrolled count; ClinicalTrials.gov record NCT06215586, source copy `cardio:ctgov-nct06215586-2026-09-01`, retrieved 2026-10-26)
- Started: 2024-02-13 (actual) (ClinicalTrials.gov record NCT06215586, source copy `cardio:ctgov-nct06215586-2026-09-01`, retrieved 2026-10-26)
- Primary completion: 2025-09-02 (actual) (ClinicalTrials.gov record NCT06215586, source copy `cardio:ctgov-nct06215586-2026-09-01`, retrieved 2026-10-26)
- Completion: 2025-09-02 (actual) (ClinicalTrials.gov record NCT06215586, source copy `cardio:ctgov-nct06215586-2026-09-01`, retrieved 2026-10-26)
- Countries: United States; Australia; Belgium; Bulgaria; Canada; Czechia; Germany; Hungary; Italy; Netherlands; New Zealand; Poland; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT06215586, source copy `cardio:ctgov-nct06215586-2026-09-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06215586-2026-09-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
- Acronym: Cycle-2-PEF
- Condition: Heart Failure
- Condition: Heart Failure Preserved Ejection Fraction
- Condition: Cardiovascular Diseases
- Condition: Heart Diseases
- Intervention (Drug): Tovinontrine (CRD-750)
- Intervention (Drug): Placebo
- Lead sponsor: Cardurion Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry lists this organization as the lead sponsor: Cardurion Pharmaceuticals, Inc. (`cardio:org-cardurion-pharmaceuticals-inc`)

## Provenance

Content hash: 8a80fb213b2edad3aff9e62cd9e7c08fbc1796f43797a1afbab0b5e73865c490
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
